Congratulations to Izote Biosciences! We at FTW Ventures are thrilled to support this incredible team on their mission to scale precision fermentation for a variety of food, cosmetics and medical applications. Izote’s innovative approach in both strain development and an oxygen-free fermentation process will make it possible for more high-value compounds to be produced, naturally, with significantly less resources required. This is both good for business and good for the world! https://lnkd.in/gB-yEjHK
FTW Ventures’ Post
More Relevant Posts
-
I am playing my part in ensuring food security & poverty alleviation through Plant tissue culturing in 🇵🇰 I Co-founder and CEO at Plantlife Biotech I MBA Candidate at IBA.
🌱 At Plantlife Biotech, we prioritize maximizing TLS/callous growth during the multiplication stage of cultures. 🌿 Our team has successfully optimized our in-house MS Media, integrating growth hormones to elevate outcomes. 💡 Through this approach, we're driving superior results and advancing innovation in plant biotechnology. 🚀 #PlantLife #Biotech #Innovation #Planttissueculture #Plantsplantsplants #Plantlifebiotech #Planttissuecultureinpakistan.
To view or add a comment, sign in
-
This is a big day for European biotechnology and for Europe. To build from the immense research base that Europe pioneered to achieve resilient food chains within Europe, reach climate goals, support agriculture, transition to biomanufacturing and provide the capacity for crisis response. It is a first step towards modernised regulation for NGTs and EuropaBio - the European Association for Bioindustries will carry the torch for micro-organisms and beyond so that we achieve a Europe that is right for citizens, the environment and the economy.
The European Commission just released its long awaited proposal for plants obtained by certain New Genomic Techniques (#NGTs). We at EuropaBio - the European Association for Bioindustries are pleased to witness this first step towards modernizing the GM framework and advocate for its expansion into micro-organisms. "𝘊𝘰𝘶𝘯𝘵𝘳𝘪𝘦𝘴 𝘸𝘰𝘳𝘭𝘥𝘸𝘪𝘥𝘦 𝘩𝘢𝘷𝘦 𝘢𝘭𝘳𝘦𝘢𝘥𝘺 𝘢𝘥𝘰𝘱𝘵𝘦𝘥 𝘳𝘦𝘨𝘶𝘭𝘢𝘵𝘰𝘳𝘺 𝘧𝘳𝘢𝘮𝘦𝘸𝘰𝘳𝘬𝘴 𝘵𝘩𝘢𝘵 𝘴𝘶𝘱𝘱𝘰𝘳𝘵 𝘮𝘢𝘳𝘬𝘦𝘵 𝘢𝘤𝘤𝘦𝘴𝘴 𝘧𝘰𝘳 𝘪𝘯𝘯𝘰𝘷𝘢𝘵𝘪𝘷𝘦 𝘣𝘪𝘰𝘵𝘦𝘤𝘩𝘯𝘰𝘭𝘰𝘨𝘺 𝘱𝘳𝘰𝘥𝘶𝘤𝘵𝘴 𝘢𝘯𝘥 𝘱𝘳𝘰𝘤𝘦𝘴𝘴𝘦𝘴 𝘢𝘯𝘥 𝘪𝘵 𝘮𝘢𝘳𝘬𝘴 𝘢 𝘨𝘭𝘰𝘣𝘢𝘭 𝘪𝘯𝘥𝘶𝘴𝘵𝘳𝘪𝘢𝘭 𝘵𝘳𝘢𝘯𝘴𝘪𝘵𝘪𝘰𝘯 𝘢𝘸𝘢𝘺 𝘧𝘳𝘰𝘮 𝘧𝘰𝘴𝘴𝘪𝘭 𝘧𝘶𝘦𝘭𝘴 𝘢𝘯𝘥 𝘪𝘯𝘵𝘰 𝘣𝘪𝘰𝘦𝘤𝘰𝘯𝘰𝘮𝘺.” says EuropaBio's Director General Claire Skentelbery. The proposal acknowledges the significance of new genomic techniques as valuable assets within Europe's toolbox of sustainable and resilient solutions. However, "𝘸𝘩𝘢𝘵 𝘪𝘴 𝘧𝘶𝘳𝘵𝘩𝘦𝘳 𝘯𝘦𝘦𝘥𝘦𝘥 𝘪𝘴 𝘳𝘦𝘤𝘰𝘨𝘯𝘪𝘵𝘪𝘰𝘯 𝘰𝘧 𝘵𝘩𝘦 𝘰𝘵𝘩𝘦𝘳 𝘢𝘱𝘱𝘭𝘪𝘤𝘢𝘵𝘪𝘰𝘯𝘴, 𝘴𝘶𝘤𝘩 𝘢𝘴 𝘮𝘪𝘤𝘳𝘰𝘰𝘳𝘨𝘢𝘯𝘪𝘴𝘮𝘴, 𝘵𝘩𝘢𝘵 𝘤𝘢𝘯 𝘤𝘰𝘯𝘵𝘳𝘪𝘣𝘶𝘵𝘦 𝘵𝘰𝘸𝘢𝘳𝘥𝘴 𝘌𝘜 𝘢𝘮𝘣𝘪𝘵𝘪𝘰𝘯𝘴 𝘶𝘯𝘥𝘦𝘳 𝘵𝘩𝘦 𝘌𝘜 𝘎𝘳𝘦𝘦𝘯 𝘋𝘦𝘢𝘭”. Dr Anne-Gaelle Collot. Hence the call from EuropaBio that discussions around new genomic techniques and the EU GM legislation need to be broader in scope. Read the full press release here: https://shorturl.at/gtOV8 w/ Lallemand | Ajinomoto Co., Inc. | Kimitec | 21st.BIO | SenseUP Biotechnology | Fréget Glaser & Associés | Phytolon | Bon Vivant | Remilk | AB Enzymes | IFF | Puratos | EV Biotech | German Chemical Industry Association VCI | Kaffe Bueno | Abolis Biotechnologies | BIO.NRW | scienceindustries | hollandbio | METEX NØØVISTAGO | BASF | Corbion | Evonik | Novozymes | dsm-firmenich | Biosafe | Meatable
The NGT proposal is an important step towards Europe’s bioeconomy-driven strategic autonomy, competitiveness and sustainability ambitions
https://www.europabio.org
To view or add a comment, sign in
-
Synonym just launched Scaler—a first-of-its-kind FREE techno-economic analysis (TEA) tool that enables fermentation companies to accelerate their path to market! 🦠 📈 Fermentation technologies carry immense potential across many different applications ranging from sustainable proteins to medicines, materials, and more. 🔑 The first step to unlocking this potential is for companies to build long-term manufacturing plans, which has proven to be a complex and costly challenge. Recognising that challenge, Synonym has made its TEA tool available to all in the synthetic biology community, thereby enabling companies to project their production and operation costs at a commercial scale. With Scaler’s customised outputs, companies can start setting their commercial roadmaps and manufacturing strategies. This is just the latest in a series of steps that Synonym has taken to accelerate commercial-scale biomanufacturing. Last year, they launched Capacitor—a tool that catalogues all existing fermentation capacity—which has quickly become the most comprehensive directory of its kind in the world. 🙌 👉 https://capacitor.bio/ 💪 Together, Capacitor and Scaler provide the fermentation ecosystem with a powerful and accessible suite of tools to guide companies along their scale-up journey. Curious as to how Scaler works? Test it out here ➡️ https://scaler.bio/
To view or add a comment, sign in
-
In recent years, we've seen precision fermentation processes make great progress in the lab, with the development of new molecules and genetic strains. But what has been kept these products from achieving mass adoption and full potential? Biomanufacturing costs. In our new report with the Boston Consulting Group (BCG), we analyze why with the exception of pharma—whose business models are mainly built on high-margin, low-volume products with low sensitivity to costs—and a few other product categories, precision fermentation and biomanufacturing have not yet proved to be economically viable at commercial scale. Enter biofoundries—facilities that are designed, built, optimized, and standardized for efficient and economic production of nonpharma bioproducts. Each such facility can provide at least 2 million liters of capacity, achieving commercial economics and bridging the cost gap by reducing unit costs by 50%. More advanced facilities, along with improved strains, can reduce production costs by up to 90%, achieving or surpassing price parity with current incumbent methods for most products. Standardization and optimization provide biofoundries with significant advantages over existing large-scale biomanufacturing facilities, particularly with respect to cost, timeline, and adaptability. This approach not only mitigates risks but also helps make biofoundries a versatile solution that can meet evolving needs and advances in future strains. Serving the $200 billion market for specialty bioproducts will require a 20-fold expansion of current production capacity. That's a lot of capacity to develop and build and the Synonym team is up to the challenge. For more on the biofoundries and their growing importance in the biomanufacturing industry, check out our full report with the Boston Consulting Group (BCG) linked in the comments. #biomanufacturing #bioeconomy #fermentation #precisionfermentation #biotech #sustainability #materialstransition #foodtech #alternativeprotein #specialtychemicals #synbio
To view or add a comment, sign in
-
It was a great collaboration to map out what bio-based, bio-inspired and biotechnologies can do to reduce food loss and waste. Because we can’t fight #foodloss and #foodwaste with diversion. #bioengineering #biotechnology
We are just wrapping up this 2023 special issue of Elsevier's Current Opinion in Biotechnology. It addresses current and on-the-horizon biotechnologies and bioinspired approaches to reduce loss and waste of foods of plant origin. Many interesting short articles with information that can add to efforts toward global sustainability. Thanks Max Teplitski for the great idea. https://lnkd.in/eFz886qr
Food Biotechnology (2023)
sciencedirect.com
To view or add a comment, sign in
-
The future of cell manufacturing is full of potential. From pioneering a revolutionary new food system to developing transformative treatments and groundbreaking medicines, cell manufacturing is at the core of positive progress in the years ahead. Our new trend report dives into the factors that will drive success at a commercial scale, as well as highlighting core challenges and opportunities in the field. Combining insights from a curated selection of experts and the results of our industry-wide survey, the report shows scaling up is key to making cell-manufactured products commercially viable, and by embracing automated processes and addressing the inefficiencies at the processing stage, manufacturers can unleash their ambitions – meeting the demands of a growing market. Get your copy of the report here: https://lnkd.in/eVxABmQD #cellmanufacturing #biomanufacturing #cellculture #bioprocessing #alternativeprotein #futureoffood #futureoffarming #smartagriculture #cellproliferation #processautomation #cellculturedmeat #biosciences #foodproduction #cellbasedmeat #sustainablefoodsystems #regenerativeagriculture #productivityimprovement #biotechnology
To view or add a comment, sign in
-
We are pleased to present another of our portfolio companies to you today: Nuritas 🌱 Nuritas is a biotechnology company from Ireland and US. It is using #AI to revolutionize the discovery of novel and natural active ingredients found in plants and natural food sources called #peptides. Their approach allows them to rapidly and efficiently predict and unlock the most health-benefiting components, creating better or new product solutions for their partners' customers. 💪 So far, Nuritas has established the world's largest peptide #knowledgebase. They can analyze billions of hidden peptides in natural food sources to identify their impact on specific health areas. Their #technology allows them to discover and develop new bioactives faster and with higher accuracy than traditional methods, at a lower cost. They aim to improve human health while making the food system more sustainable by replacing unwanted ingredients and molecules with more natural and sustainable ones. 🌿 Nuritas harnesses the power of nature through innovation and tries to positively impact the lives of many people. We are enlightened to support Nuritas in their goal to promote natural and healthier living by creating everyday products that are safer, greener, and more effective. 🤲🌱
To view or add a comment, sign in
957 followers